LAVA Therapeutics (LVTX)

• Market cap: $40.5M
• 1 day: 0%
• 5 days: -0.65%
• 1 month: 0.65%
• 3 months: 17.56%
• 6 months: 14.07%
• Year to date: 49.51%
• 1 year: -8.33%
• 5 years: -89.23%
• 10 years: -89.23%
• Sector: Healthcare
• Industry: Biotechnology

About: LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.

Employees: 34

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

50% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 3 (+1) [Q2]

4% more capital invested

Capital invested by funds: $10.2M [Q1] → $10.6M (+$411K) [Q2]

0.01% more ownership

Funds ownership: 30.6% [Q1] → 30.61% (+0.01%) [Q2]

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

5% less funds holding

Funds holding: 20 [Q1] → 19 (-1) [Q2]

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $1.24
• Avg. target: $1.37
• High target: $1.5

2 analyst ratings

• positive: 0 0%
• neutral: 2 100%
• negative: 0 0%

HC Wainwright & Co. Arthur He	$1.24	Neutral Maintained	5 Aug 2025
Jefferies Roger Song	$1.5	Hold Downgraded	5 Aug 2025